Promab: NantKwest and ProMab partner to develop NK cell therapies
Immunotherapy company NantKwest has partnered with ProMab Biotechnologies with the aim of developing a select next generation targeted natural killer...Read More...The post NantKwest and ProMab partner to develop NK cell therapies appeared first on Pharmaceutical Technology.
Read full article »
Promab develops and commercializes recombinant proteins and antibodies through the integration of bioinformatics, gene cloning and immunology.
Read more